115 related articles for article (PubMed ID: 27268696)
1. Novel substituted isoxazole FXR agonists with cyclopropyl, hydroxycyclobutyl and hydroxyazetidinyl linkers: Understanding and improving key determinants of pharmacological properties.
Kinzel O; Steeneck C; Schlüter T; Schulz A; Gege C; Hahn U; Hambruch E; Hornberger M; Spalwisz A; Frick K; Perović-Ottstadt S; Deuschle U; Burnet M; Kremoser C
Bioorg Med Chem Lett; 2016 Aug; 26(15):3746-53. PubMed ID: 27268696
[TBL] [Abstract][Full Text] [Related]
2. Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064.
Bass JY; Caldwell RD; Caravella JA; Chen L; Creech KL; Deaton DN; Madauss KP; Marr HB; McFadyen RB; Miller AB; Parks DJ; Todd D; Williams SP; Wisely GB
Bioorg Med Chem Lett; 2009 Jun; 19(11):2969-73. PubMed ID: 19410460
[TBL] [Abstract][Full Text] [Related]
3. Knocking on FXR's door: the "hammerhead"-structure series of FXR agonists - amphiphilic isoxazoles with potent in vitro and in vivo activities.
Gege C; Kinzel O; Steeneck C; Schulz A; Kremoser C
Curr Top Med Chem; 2014; 14(19):2143-58. PubMed ID: 25388536
[TBL] [Abstract][Full Text] [Related]
4. Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.
Flesch D; Gabler M; Lill A; Gomez RC; Steri R; Schneider G; Stark H; Schubert-Zsilavecz M; Merk D
Bioorg Med Chem; 2015 Jul; 23(13):3490-8. PubMed ID: 25934227
[TBL] [Abstract][Full Text] [Related]
5. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice.
Hambruch E; Miyazaki-Anzai S; Hahn U; Matysik S; Boettcher A; Perović-Ottstadt S; Schlüter T; Kinzel O; Krol HD; Deuschle U; Burnet M; Levi M; Schmitz G; Miyazaki M; Kremoser C
J Pharmacol Exp Ther; 2012 Dec; 343(3):556-67. PubMed ID: 22918042
[TBL] [Abstract][Full Text] [Related]
6. Structure-guided modification of isoxazole-type FXR agonists: Identification of a potent and orally bioavailable FXR modulator.
Luo G; Lin X; Li Z; Xiao M; Li X; Zhang D; Xiang H
Eur J Med Chem; 2021 Jan; 209():112910. PubMed ID: 33049605
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of Novel Farnesoid X Receptor Agonists and Validation of Their Efficacy in Activating Differentiation of Mouse Bone Marrow-Derived Mesenchymal Stem Cells into Osteoblasts.
Fujimori K; Iguchi Y; Yamashita Y; Gohda K; Teno N
Molecules; 2019 Nov; 24(22):. PubMed ID: 31744088
[TBL] [Abstract][Full Text] [Related]
8. Novel heterocyclic scaffolds of GW4064 as farnesoid X receptor agonists.
Smalley TL; Boggs S; Caravella JA; Chen L; Creech KL; Deaton DN; Kaldor I; Parks DJ
Bioorg Med Chem Lett; 2015 Jan; 25(2):280-4. PubMed ID: 25499883
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and Biological Evaluation of Novel Nonsteroidal Farnesoid X Receptor (FXR) Antagonists: Molecular Basis of FXR Antagonism.
Huang H; Si P; Wang L; Xu Y; Xu X; Zhu J; Jiang H; Li W; Chen L; Li J
ChemMedChem; 2015 Jul; 10(7):1184-99. PubMed ID: 25982493
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.
Abel U; Schlüter T; Schulz A; Hambruch E; Steeneck C; Hornberger M; Hoffmann T; Perović-Ottstadt S; Kinzel O; Burnet M; Deuschle U; Kremoser C
Bioorg Med Chem Lett; 2010 Aug; 20(16):4911-7. PubMed ID: 20638278
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH).
Tully DC; Rucker PV; Chianelli D; Williams J; Vidal A; Alper PB; Mutnick D; Bursulaya B; Schmeits J; Wu X; Bao D; Zoll J; Kim Y; Groessl T; McNamara P; Seidel HM; Molteni V; Liu B; Phimister A; Joseph SB; Laffitte B
J Med Chem; 2017 Dec; 60(24):9960-9973. PubMed ID: 29148806
[TBL] [Abstract][Full Text] [Related]
12. Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist.
Feng S; Yang M; Zhang Z; Wang Z; Hong D; Richter H; Benson GM; Bleicher K; Grether U; Martin RE; Plancher JM; Kuhn B; Rudolph MG; Chen L
Bioorg Med Chem Lett; 2009 May; 19(9):2595-8. PubMed ID: 19328688
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia.
Genin MJ; Bueno AB; Agejas Francisco J; Manninen PR; Bocchinfuso WP; Montrose-Rafizadeh C; Cannady EA; Jones TM; Stille JR; Raddad E; Reidy C; Cox A; Michael MD; Michael LF
J Med Chem; 2015 Dec; 58(24):9768-72. PubMed ID: 26568144
[TBL] [Abstract][Full Text] [Related]
14. Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.
Akwabi-Ameyaw A; Bass JY; Caldwell RD; Caravella JA; Chen L; Creech KL; Deaton DN; Jones SA; Kaldor I; Liu Y; Madauss KP; Marr HB; McFadyen RB; Miller AB; Navas F; Parks DJ; Spearing PK; Todd D; Williams SP; Wisely GB
Bioorg Med Chem Lett; 2008 Aug; 18(15):4339-43. PubMed ID: 18621523
[TBL] [Abstract][Full Text] [Related]
15. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation.
Yao J; Zhou CS; Ma X; Fu BQ; Tao LS; Chen M; Xu YP
World J Gastroenterol; 2014 Oct; 20(39):14430-41. PubMed ID: 25339829
[TBL] [Abstract][Full Text] [Related]
16. Farnesoid X receptor agonist GW4064 indirectly inhibits HCV entry into cells via down-regulating scavenger receptor class B type I.
Wu ZY; Li H; Li JR; Lv XQ; Jiang JD; Peng ZG
Eur J Pharmacol; 2019 Jun; 853():111-120. PubMed ID: 30902657
[TBL] [Abstract][Full Text] [Related]
17. Restoration of enterohepatic bile acid pathways in pregnant mice following short term activation of Fxr by GW4064.
Moscovitz JE; Kong B; Buckley K; Buckley B; Guo GL; Aleksunes LM
Toxicol Appl Pharmacol; 2016 Nov; 310():60-67. PubMed ID: 27609522
[TBL] [Abstract][Full Text] [Related]
18. Unbinding pathways of GW4064 from human farnesoid X receptor as revealed by molecular dynamics simulations.
Li W; Fu J; Cheng F; Zheng M; Zhang J; Liu G; Tang Y
J Chem Inf Model; 2012 Nov; 52(11):3043-52. PubMed ID: 23101941
[TBL] [Abstract][Full Text] [Related]
19. A formulation-enabled preclinical efficacy assessment of a farnesoid X receptor agonist, GW4064, in hamsters and cynomolgus monkeys.
Chiang PC; Thompson DC; Ghosh S; Heitmeier MR
J Pharm Sci; 2011 Nov; 100(11):4722-33. PubMed ID: 21660973
[TBL] [Abstract][Full Text] [Related]
20. Conformationally constrained farnesoid X receptor (FXR) agonists: heteroaryl replacements of the naphthalene.
Bass JY; Caravella JA; Chen L; Creech KL; Deaton DN; Madauss KP; Marr HB; McFadyen RB; Miller AB; Mills WY; Navas F; Parks DJ; Smalley TL; Spearing PK; Todd D; Williams SP; Wisely GB
Bioorg Med Chem Lett; 2011 Feb; 21(4):1206-13. PubMed ID: 21256005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
